Substance / Medication

Lusutrombopag

Overview

Active Ingredient
lusutrombopag
RxNorm CUI
2054984

Indications

MULPLETA is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

Labeler: VANCOCIN ITALIA SRLUpdated: 2025-12-09T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

14 trials linked to this intervention

14
Total Trials
5
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma.
Alkhouri Naim, Imawari Michio, Izumi Namiki et al. · Clin Gastroenterol Hepatol · 2020
PMID: 32205226Meta-Analysis
Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters.
Katsube Takayuki, Inoue Yuji, Fukuhara Takahiro et al. · Eur J Clin Pharmacol · 2020
PMID: 32666123RCTFull text (PMC)
Effects of Food and Calcium Carbonate on the Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist.
Katsube Takayuki, Wajima Toshihiro, Fukuhara Takahiro et al. · Clin Ther · 2019
PMID: 31303281RCT
Lusutrombopag has slightly stronger effects on patients with mild thrombocytopenia compared with those with severe thrombocytopenia: A multicenter propensity score matching study.
Furuichi Yoshihiro, Takeuchi Hirohito, Uojima Haruki et al. · J Hepatobiliary Pancreat Sci · 2022
PMID: 34953107Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Lusutrombopag (substance)
SNOMED CT
773265003
UMLS CUI
C4309207
RxNorm CUI
2054984
Labeler
VANCOCIN ITALIA SRL

Clinical Data

This intervention maps to 7 entities in the Ltrl knowledge graph.

1
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
14
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.